NCT01083706 · OUTCOME

Overall Survival

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant · Source last updated 2017-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 6 months

What was measured

Count of surviving participants at 6 months.

Groups in this outcome

Treatment (Chemotherapy)

Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. azacitidine: Given SC or IV laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Chemotherapy)	39

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Chemotherapy)	25	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
25

denoms

counts
group Id
OG000
value
39
units
Participants

description

Count of surviving participants at 6 months.

groups

description
Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. azacitidine: Given SC or IV laboratory biomarker analysis: Correlative studies
id
OG000
title
Treatment (Chemotherapy)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

6 months

title

Overall Survival

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice